Literature DB >> 11358379

Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes.

E H Abraham1, B Shrivastav, A Y Salikhova, K M Sterling, N Johnston, G Guidotti, S Scala, T Litman, K C Chan, R J Arceci, K Steiglitz, L Herscher, P Okunieff.   

Abstract

P-glycoprotein is involved with the removal of drugs, most of them cations, from the plasma membrane and cytoplasm. Pgp is also associated with movement of ATP, an anion, from the cytoplasm to the extracellular space. The central question of this study is whether drug and ATP transport associated with the expression of Pgp are in any way coupled. We have measured the stoichiometry of transport coupling between drug and ATP release. The drug and ATP transport that is inhibitable by the sulfonylurea compound, glyburide (P. E. Golstein, A. Boom, J. van Geffel, P. Jacobs, B. Masereel, and R. Beauwens, Pfluger's Arch. 437, 652, 1999), permits determination of the transport coupling ratio, which is close to 1:1. In view of this result, we asked whether ATP interacts directly with Pgp substrates. We show by measuring the movement of Pgp substrates in electric fields that ATP and drug movement are coupled. The results are compatible with the view that substrates for Pgp efflux are driven by the movement of ATP through electrostatic interaction and effective ATP-drug complex formation with net anionic character. This mechanism not only pertains to drug efflux from tumor cells overexpressing Pgp, but also provides a framework for understanding the role of erythrocytes in drug resistance. The erythrocyte consists of a membrane surrounding a millimolar pool of ATP. Mammalian RBCs have no nucleus or DNA drug/toxin targets. From the perspective of drug/ATP complex formation, the RBC serves as an important electrochemical sink for toxins. The presence in the erythrocyte membrane of approximately 100 Pgp copies per RBC provides a mechanism for eventual toxin clearance. The RBC transport of toxins permits their removal from sensitive structures and ultimate clearance from the organism via the liver and/or kidneys. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358379     DOI: 10.1006/bcmd.2000.0373

Source DB:  PubMed          Journal:  Blood Cells Mol Dis        ISSN: 1079-9796            Impact factor:   3.039


  5 in total

1.  Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes.

Authors:  Chung-Pu Wu; Antonios Klokouzas; Stephen B Hladky; Suresh V Ambudkar; Margery A Barrand
Journal:  Biochem Pharmacol       Date:  2005-08-15       Impact factor: 5.858

Review 2.  Maternal-fetal transport of hypoglycaemic drugs.

Authors:  Facundo Garcia-Bournissen; Denice S Feig; Gideon Koren
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  The role of multidrug resistance protein 1 (MRP1) in transport of fluorescent anions across the human erythrocyte membrane.

Authors:  B Rychlik; A Balcerczyk; A Klimczak; G Bartosz
Journal:  J Membr Biol       Date:  2003-05-15       Impact factor: 1.843

Review 4.  Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: relevance for physiology and pharmacotherapy.

Authors:  Kathleen Köck; Markus Grube; Gabriele Jedlitschky; Lena Oevermann; Werner Siegmund; Christoph A Ritter; Heyo K Kroemer
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  ATP release via anion channels.

Authors:  Ravshan Z Sabirov; Yasunobu Okada
Journal:  Purinergic Signal       Date:  2005-12-03       Impact factor: 3.765

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.